28 5.7 FLOW CHART – TREATMENT GUIDELINES FOR CHRONIC ENDOPHTHALMITIS (presumed <strong>and</strong> not proven) [205] Make a clinical diagnosis Investigate for a microbial source CONDUCT A TRIAL OF THERAPY WITH CLARITHROMYCIN 250mg twice daily for two weeks (this derivative <strong>of</strong> erythromycin is well absorbed orally, penetrates well into the eye <strong>and</strong> is c<strong>on</strong>centrated 200 times into PMNs <strong>and</strong> macrophages, to kill intra-cellular Gram-positive bacteria <strong>and</strong> Haemophilus sp., but not other Gram-negative rods; clarithromycin is also effective against many atypical bacteria) [115], [201], [205] If successful, retain IOL but if therapy fails, make a decisi<strong>on</strong> <strong>on</strong> whether to retain or remove the IOL <strong>and</strong> c<strong>on</strong>sider performing a vitrectomy possibly combined with a posterior capsulectomy [160] If IOL is retained, give trial <strong>of</strong> therapy with intravitreal vancomycin <strong>and</strong> cefazolin or cefuroxime, together with intravenous therapy for <strong>on</strong>e week If combinati<strong>on</strong> anti-microbial therapy fails as well, remove the IOL – collect samples <strong>of</strong> capsule fragment for histology, electr<strong>on</strong> microscopy <strong>and</strong> microbiology investigati<strong>on</strong> (Gram stain, culture & PCR) [47], [202], [205] Inflammati<strong>on</strong> usually subsides after the IOL has been removed with the capsule but further antibiotic therapy can be given, such as an oral quinol<strong>on</strong>e, but may not be needed
6. References References categorised as EbM IB [1] Barry, P., Seal, D. V., Gettinby, G., Lees, F., Peters<strong>on</strong>, M., Revie, C. W.: <str<strong>on</strong>g>ESCRS</str<strong>on</strong>g> study <strong>of</strong> prophylaxis <strong>of</strong> post-operative endophthalmitis after cataract surgery: Preliminary report <strong>of</strong> principal results from a European multi-centre study. J Cataract Refract Surg. 32, 2006, 407 - 410 [2] Bucci, F. A.: An In Vivo Study Comparing the Ocular Absorpti<strong>on</strong> <strong>of</strong> Lev<strong>of</strong>loxacin <strong>and</strong> Cipr<strong>of</strong>loxacin Prior to Phacoemulsificati<strong>on</strong>. Am J Ophthalmol 137, 2004, 308 - 312 [3] Colin, J., Sim<strong>on</strong>poli, S., Geldsetzer, K., Ropo, A.: Corneal penetrati<strong>on</strong> <strong>of</strong> lev<strong>of</strong>loxacin into the human aqueous humour: a comparis<strong>on</strong> with cipr<strong>of</strong>loxacin. Acta Ophthalmol Sc<strong>and</strong> 81, 2003, 611 - 613 [4] D<strong>of</strong>t, B. H., Wisniewski, S. R., Kelsey, S. F., Fitzgerald, S. G., Endophthalmitis Vitrectomy Study Group: Diabetes <strong>and</strong> postoperative endophthalmitis in the Endophthalmitis Vitrectomy Study. Arch Ophthalmol 119, 2001, 650 - 656 [5] <str<strong>on</strong>g>ESCRS</str<strong>on</strong>g> Endophthalmitis Study Group: Prophylaxis <strong>of</strong> post-operative endophthalmitis following cataract surgery: results <strong>of</strong> the <str<strong>on</strong>g>ESCRS</str<strong>on</strong>g> multi-centre study <strong>and</strong> identificati<strong>on</strong> <strong>of</strong> risk factors. J Cataract Refract Surg. 33, 2007, 978 - 988 [6] Kobayakawa, S., Tochikubo, T., Tsuji, A.: Penetrati<strong>on</strong> <strong>of</strong> Lev<strong>of</strong>loxacin into Human Aqueous Humor. Ophthalmic Res 35, 2003, 97 - 101 [7] Koch, H.-R., Kulus, S. C., Roessler, M., Ropo, A., Geldsetzer, K.: Corneal penetrati<strong>on</strong> <strong>of</strong> fluoroquinol<strong>on</strong>es: aqueous humour c<strong>on</strong>centrati<strong>on</strong>s after topical applicati<strong>on</strong> <strong>of</strong> lev<strong>of</strong>loxacin 0.5% <strong>and</strong> <strong>of</strong>loxacin 0.3% eyedrops. J Cataract Refract Surg 31, 2005, 1377 - 1385 [8] Nagaki, Y., Hayasaka, S., Kadoi, C., Matsumoto, M., Yanagisawa, S., Watanabe, Ka., Watanabe, Ko., Hayasaka, Y., Ikeda, N., Sato., S., Kataoka, Y., Togashi, M., Abe, T.: Bacterial endophthalmitis after small-incisi<strong>on</strong> cataract surgery. Effect <strong>of</strong> incisi<strong>on</strong> placement <strong>and</strong> intraocular lens type. J Cataract Refract Surg 29, 2003, 20 - 26 [9] Narang, S., Gupta, V., Gupta, A., Dogra, M. R., P<strong>and</strong>av, S. S., Das, S.: Role <strong>of</strong> prophylactic intravitreal antibiotics in open globe injuries. Indian J Ophthalmol. 51, 2003, 39 - 44 [10] Seal, D. V., Barry, P., Gettinby, G., Lees, F., Peters<strong>on</strong>, M., Revie, C. W., Wilhelmus, K. R.: <str<strong>on</strong>g>ESCRS</str<strong>on</strong>g> study <strong>of</strong> prophylaxis <strong>of</strong> postoperative endophthalmitis after cataract surgery: Case for a European multi-centre study. J Cataract Refract Surg. 32, 2006, 396 - 406 [11] Seal, D. V., Reischl, U., Behr, A., Ferrer, C., Alio, J., Koerner, R., Barry, P., <str<strong>on</strong>g>ESCRS</str<strong>on</strong>g> Endophthalmitis Study Group: Laboratory <strong>management</strong> <strong>of</strong> endophthalmitis: comparis<strong>on</strong> <strong>of</strong> microbiology <strong>and</strong> molecular biology methods in the European multi-centre study <strong>and</strong> appropriate chemotherapy. Manuscript in preparati<strong>on</strong>. [12] Seal, D., Wright, P., Ficker, L., Hagan, K., Troski, M., Menday, P. : Placebo-c<strong>on</strong>trolled trial <strong>of</strong> fusidic acid gel <strong>and</strong> oxytetracycline for recurrent blepharitis <strong>and</strong> rosacea. Br J Ophthalmol 79, 1995, 42 - 45 [13] Soheilian, M., Rafati N., Mohebbi, M. R., Yazdani, S., Habibabadi, H. F., Feghhi, M., Shahriary, H. A., Eslamipour, J., Piri, N., Peyman, G. A.: Traumatic Endophthalmitis Trial Research Group: Prophylaxis <strong>of</strong> acute posttraumatic bacterial endophthalmitis: a multi-centre, r<strong>and</strong>omized clinical trial <strong>of</strong> intraocular antibiotic injecti<strong>on</strong>, report 2. Arch Ophthalmol 125, 2007, 460 - 465 [14] Soheilian, M., Rafati N., Peyman, G. A.: Prophylaxis <strong>of</strong> acute posttraumatic bacterial endophthalmitis with or without combined intraocular antibiotics: a prospective, double-masked r<strong>and</strong>omized pilot study. Int Ophthalmol 24, 2001, 323 - 330 References categorised as EbM IIA [15] Endophthalmitis Vitrectomy Study Group: Results <strong>of</strong> the Endophthalmitis Vitrectomy Study. A r<strong>and</strong>omized trial <strong>of</strong> immediate vitrectomy <strong>and</strong> <strong>of</strong> intravenous antibiotics for the treatment <strong>of</strong> post-operative bacterial endophthalmitis. Arch Ophthalmol 113, 1995, 1479 - 1496 [16] Kramer, A., Below, H., Behrens-Baumann, W., Müller, G., Rudolph, P., Reimer, K.: New aspects <strong>of</strong> the tolerance <strong>of</strong> the antiseptic povid<strong>on</strong>e-iodine in different ex vivo models. Dermatol 204 (Suppl. 1), 2001, 86 - 91 [17] Rudolph, P., Reimer, K., Mlynski, G., Reese, M., Kramer, A.: Modell zur Ermittlung der Nasenverträglichkeit lokaler Antiinfektiva mittels In-vitro-Bestimmung der Ziliaraktivität. Hyg Med 25, 2000, 500 - 503 [18] Speaker, M. G. <strong>and</strong> Menik<strong>of</strong>f, J. A.: Prophylaxis <strong>of</strong> endophthalmitis with topical povid<strong>on</strong>e-iodine. Ophthalmology 98, 1991, 1769 - 1775 References categorised as EbM IIB [19] Alio, J., Ferrer, C., Fern<strong>and</strong>ez, J., Abad, J.L., Rodriguez, A.: Intravitreal lev<strong>of</strong>loxacin m<strong>on</strong>otherapy <strong>of</strong> endophthalmitis in an experimental model. Presented at Winter <str<strong>on</strong>g>ESCRS</str<strong>on</strong>g> Meeting, Rome 2005. Abstract, manuscript submitted to BJO [20] Barza, M., Pavan, P. R., D<strong>of</strong>t, B. H., Wisniewski, S. R., Wils<strong>on</strong>, L. A., Han, D. P., Kelsey, S. F.: Evaluati<strong>on</strong> <strong>of</strong> microbiological diagnostic techniques in post-operative endophthalmitis in the Endophthalmitis Vitrectomy Study. Arch Ophthalmol 115, 1997, 1142 - 1150 [21] Behrens-Baumann, W., Martell, J.: Cipr<strong>of</strong>loxacin c<strong>on</strong>centrati<strong>on</strong>s in human aqueous humor following intravenous administrati<strong>on</strong>. Chemoth 33, 1987, 328 - 330 [22] Binder, C. A., Miño de Kaspar, H., Engelbert, M., Klauß, V., Kampik, A.: Bakterielle Keimbesiedelung der K<strong>on</strong>junktiva mit Propi<strong>on</strong>ibacterium acnes vor und nach Polyvid<strong>on</strong>-Jod-Applikati<strong>on</strong> vor intraokulären Eingriffen. Ophthalmologe 95, 1998, 438 - 441 [23] Binder, C. A., Miño de Kaspar, H., Klauß, V., Kampik, A.: Präoperative Infekti<strong>on</strong>sprophylaxe mit 1%-iger Polyvid<strong>on</strong>-Jod-Lösung am Beispiel v<strong>on</strong> k<strong>on</strong>junktivalen Staphylokokken. Ophthalmologe 96, 1999, 663 - 667 [24] Engstrom, R. E. Jr., M<strong>on</strong>dino, B. J., Glasgow, B. J., Pitchekian-Halabi, H., Adamu, S. A.: Immune resp<strong>on</strong>se to Staphylococcus aureus endophthalmitis in a rabbit model. Invest Ophthalmol Vis Sci 32, 1991, 1523 - 1533 [25] Forster, R. K.: Experimental post-operative endophthalmitis. Trans Am Ophthalmol Soc 90, 1992, 505 - 559 [26] Healy, D. P., Holl<strong>and</strong>, E. J., Nordlund, M. L., Dunn, S., Chow, C., Lindstrom, R. L., Hardten, D., Davis, E.: C<strong>on</strong>centrati<strong>on</strong>s <strong>of</strong> lev<strong>of</strong>loxacin, <strong>of</strong>loxacin <strong>and</strong> cipr<strong>of</strong>loxacin in human corneal stromal tissue <strong>and</strong> aqueous humor after topical administrati<strong>on</strong>. Cornea 23, 2004, 255 - 263 29
- Page 1 and 2: ESCRS Guid
- Page 3 and 4: 1. Introduction 1.1 Endophthalmitis
- Page 5 and 6: In the ESCRS Study
- Page 7 and 8: In a case-control study of post-ope
- Page 9 and 10: Medical conditions Diabetes mellitu
- Page 11 and 12: In 1991, Bohigian was able to show
- Page 13 and 14: Intra-operative prophylaxis Additio
- Page 15 and 16: Levofloxacin was chosen as a topica
- Page 17 and 18: 3. Diagnosis 3.1 Commencement and s
- Page 19 and 20: 3.3 FLOW CHART - DIAGNOSTIC GUIDELI
- Page 21 and 22: 4. Investigation 4.1 AC tap, vitreo
- Page 23 and 24: Figure 5.1 Portable Vitrector* - Be
- Page 25 and 26: How To Make Up The Antibiotics The
- Page 27 and 28: abbits but the final dose to use, t
- Page 29: 5.6 FLOW CHART - TREATMENT GUIDELIN
- Page 33 and 34: [57] Brinton, G. S., Topping, T. M.
- Page 35 and 36: [121] Pflugfelder, St. C., Flynn, H
- Page 37 and 38: [190] Ng, E. W., Barrett, G. D., Bo
- Page 39 and 40: Notes 37